Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Falkensee – page 88

1 865 clinical trials in Falkensee, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Falkensee at a glance
1 865
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 865 trials in Falkensee

Open in trial search

Dermatitis atopic

Not recruiting

Study on Tralokinumab and Topical Corticosteroids for Children and Infants with Moderate-to-Severe Atopic Dermatitis

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Tralokinumab
  • Sponsor:Leo Pharma A/S

Study of Pembrolizumab and Drug Combination for Patients with Advanced Esophageal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Efficacy Comparison of Zanzalintinib (XL092) and Pembrolizumab Versus Pembrolizumab Monotherapy in PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Exelixis Inc.

Drug level

Not recruiting

Study of BI 1810631 oral bioavailability in healthy men under fed vs fasted conditions

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Zongertinib
  • Sponsor:Boehringer Ingelheim International GmbH

Major depression

Not recruiting

A study to compare the safety of ketamine hydrochloride and esketamine in healthy men for the treatment of depression

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · Healthy volunteers
  • Substances:Esketamine Hydrochloride
  • Sponsor:Ketabon GmbH

Study on Estriol Vaginal Ring for Treating Vaginal Atrophy in Postmenopausal Women

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Estriol
  • Sponsor:SocraTec R&D Concepts in Drug Research and Development GmbH

Crohn's disease

Not recruiting

Study on Guselkumab for Patients with Moderate to Severe Crohn's Disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study of Sotatercept for Newly Diagnosed Intermediate- and High-risk Pulmonary Arterial Hypertension Patients

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sotatercept
  • Sponsor:Acceleron Pharma Inc.

Arteriosclerosis+2

Not recruiting

Long-term Safety Study of INZ-701 for Patients with ENPP1 and ABCC6 Deficiencies, Including Pseudoxanthoma Elasticum and Generalized Arterial Calcification of Infancy

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Recombinant Human Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 Fused To The Fc Fragment Of Igg1
  • Sponsor:Inozyme Pharma Inc.

Study on the Effects of Upadacitinib in Adults with Moderate to Severe Systemic Lupus Erythematosus (SLE)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer

Not recruiting

Study of Camizestrant plus Ribociclib as First‑Line Treatment for Patients with ER‑Positive, HER2‑Negative Advanced Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Falkensee

What the registry says about research in the country

01 Metabolic Disorders

Innovative research focusing on Type 2 Diabetes Mellitus management and glycemic control, evaluating new therapeutic approaches including novel compounds and established treatments.

  • Glycemic Control Studies
  • Cardiovascular Outcomes
  • Diabetes Management

Multiple trials are investigating both single and combination therapies for improving patient outcomes.

02 Cardiovascular Health

Comprehensive studies addressing atherosclerotic cardiovascular disease and cholesterol management, examining innovative treatments for reducing major adverse cardiovascular events.

  • Lipid Management
  • Cardiovascular Risk Reduction
  • Arterial Health

Research focuses on comparing effectiveness of different therapeutic approaches for cholesterol control.

03 Metabolic and Renal Health

Groundbreaking research combining treatments for chronic kidney disease and metabolic conditions, including studies on weight management and obesity-related complications.

  • Weight Management
  • Kidney Disease Progression
  • Blood Pressure Control

Trials evaluate combination therapies targeting multiple health conditions simultaneously.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.